What is Leerink Partnrs' Forecast for Pharvaris Q1 Earnings?

Pharvaris (NASDAQ:PHVS - Free Report) - Equities researchers at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for Pharvaris in a research report issued on Monday, April 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($0.91) per share for the quarter, down from their previous forecast of ($0.74). The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Pharvaris' Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($3.63) EPS and FY2026 earnings at ($3.39) EPS.

Separately, JMP Securities lifted their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.

Pharvaris Stock Performance

PHVS traded up $0.68 during mid-day trading on Thursday, reaching $13.30. The stock had a trading volume of 14,342 shares, compared to its average volume of 71,224. The firm's fifty day simple moving average is $15.45 and its two-hundred day simple moving average is $18.32. The stock has a market capitalization of $695.46 million, a P/E ratio of -4.75 and a beta of -2.84. Pharvaris has a 52 week low of $11.51 and a 52 week high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Monday, April 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.06.

Institutional Investors Weigh In On Pharvaris

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio acquired a new position in shares of Pharvaris during the 3rd quarter worth about $57,000. JPMorgan Chase & Co. grew its holdings in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after purchasing an additional 2,847 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Pharvaris in the fourth quarter valued at approximately $64,000. Barclays PLC acquired a new stake in Pharvaris in the third quarter worth $106,000. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Pharvaris during the fourth quarter worth $111,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.